Skip to main content
Back to feed
MarketsCorroboratingMedium
5.4

Citi: Eli Lilly Extends GLP-1 Lead Over Novo in US Market

Citi analysis indicates Eli Lilly is widening its competitive advantage over Novo Nordisk in the US GLP-1 market, a key growth segment. The shift reflects Lilly's supply and commercial execution, pressuring Novo's growth outlook. Market share dynamics in this high-demand category are material for both companies' earnings.

Dagens Industriabout 6 hours agoUS, DKCredibility 26%View source

Score Breakdown

Mosaic Score5.4
Confidence0.5
Significance0.5
Source credibility0.3

Intelligence Tags

#glp-1#eli-lilly#novo-nordisk#pharmaceuticals#market-share

Entities

country
Source

Related signals

8 found